Population pharmacokinetics of ABT-594 in subjects with diabetic peripheral neuropathic pain.

What is known and Objective: ABT-594 is a non-opioid, non-NSAID analgesic. The objective of this work was to characterize the population pharmacokinetics of ABT-594 in subjects with neuropathic pain. Methods: Efficacy, safety and pharmacokinetics of ABT-594 in subjects with painful diabetic polyneur...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Clinical Pharmacy & Therapeutics Vol. 37; no. 4; pp. 475 - 481
Autores principales: Dutta, S., Awni, W.
Formato: research tables/charts Journal Article
Publicado: Wiley-Blackwell Aug2012
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104470798&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 104470798
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        02694727
        EV4
      jtl: Journal of Clinical Pharmacy & Therapeutics
      issn: 02694727
      maglogo: Y
    pubinfo:
      dt: Aug2012
      vid: 37
      iid: 4
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        104470798
        77499278
        10.1111/j.1365-2710.2011.01325.x
        NLM22145610
        104470798
      ppf: 475
      ppct: 6
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Population pharmacokinetics of ABT-594 in subjects with diabetic peripheral neuropathic pain.
      aug:
        au:
          Dutta, S.
          Awni, W.
        affil: Department of Clinical Pharmacokinetics and Pharmacodynamics, Abbott, IL; Clinical Pharmacology and Pharmacometrics, Global Pharmaceutical Research and Development, Abbott, IL, USA
      sug:
        subj:
          Diabetic Neuropathies Drug Therapy
          Analgesics Pharmacokinetics
          Heterocyclic Compounds Pharmacokinetics
          Pyridines Pharmacokinetics
          Chronic Pain Drug Therapy
          Treatment Outcomes
          Analgesics Administration and Dosage
          Analgesics Blood
          Data Analysis Software
          Descriptive Statistics
          Models, Statistical
          Parametric Statistics
          Analysis of Covariance
          Human
          Male
          Female
          Nonparametric Statistics
          Random Sample
          Adult
          Middle Age
          Aged
          Aged, 80 and Over
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Aged: 65+ years
          Aged, 80 & over
          Male
          Female
      ab: What is known and Objective: ABT-594 is a non-opioid, non-NSAID analgesic. The objective of this work was to characterize the population pharmacokinetics of ABT-594 in subjects with neuropathic pain. Methods: Efficacy, safety and pharmacokinetics of ABT-594 in subjects with painful diabetic polyneuropathy were evaluated in a randomized, double-blind, placebo-controlled, parallel-group, multi-centre, 7-week Phase 2 study. Subjects ( N = 266) were approximately equally divided into four groups to receive BID regimens of placebo or 150, 225 and 300 μg of ABT-594. ABT-594 concentrations were determined from all subjects, whereas a subset of subjects provided intensive pharmacokinetic samples on two occasions. One- and two-compartment models were explored for characterizing plasma ABT-594 concentration-time profiles. The relative importance of covariates (age, weight, body surface area, creatinine clearance, gender, nicotine use and albumin concentrations) was examined by use of the likelihood ratio test. Model building was accomplished using stepwise forward selection ( P < 0·05) and backward elimination ( P < 0·005) of covariates. Population analyses were performed using NONMEM. Results and Discussion: Optimal characterization of the plasma concentration data was achieved using a one-compartment base model. Creatinine clearance and age were found to be significant covariates in the forward selection process; backward elimination process identified only creatinine clearance as a significant covariate. What is new and Conclusion: A population pharmacokinetic model was developed to characterize ABT-594 concentrations in subjects with neuropathic pain. As ABT-594 is primarily eliminated as unchanged drug in the urine, creatinine clearance and age were significant covariates of clearance with creatinine clearance being the optimal predictor of ABT-594 clearance.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N